Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ligand Pharmaceuticals Incorporated - Common Stock (NQ:LGND)

234.83 +0.43 (+0.18%)
Streaming Delayed Price Updated: 9:43 AM EDT, Jun 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ligand Pharmaceuticals Incorporated - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Wealth Manager Sells $7 Million of Establishment Labs After Massive Gains. Is This Medical Device Stock a Buy? ↗
Establishment Labs develops advanced silicone implants and medical devices for global plastic surgery markets. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
OneSpaWorld Posted Record Revenue for Last Quarter. Why Did a Fund Exit a $21.5 Million Stake? ↗
OneSpaWorld provides spa, fitness, and beauty services to cruise and resort guests through exclusive wellness partnerships worldwide. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Is Genpact Stock a Buy After Hedge Fund Rice Hall James Raised Its Stake by $14 Million? ↗
Genpact delivers business process and IT services to global enterprises, with a diversified client base across multiple industries. 
Via The Motley Fool
Topics Artificial Intelligence Economy
Ligand Pharmaceuticals (NASDAQ:LGND) Shares Fall on Q1 Revenue and EPS Miss ↗
Via Chartmill
Ligand Pharmaceuticals (NASDAQ:LGND) Passes Minervini Trend Template and Growth Screen ↗
Via Chartmill
Ligand Pharmaceuticals (NASDAQ:LGND) Beats Q4 Estimates and Reaffirms 2026 Guidance ↗
Via Chartmill
News headline image
Is WaterBridge Stock a Buy After Ranger Investment Raised Its Stake by 345,000 Shares? ↗
WaterBridge Infrastructure delivers water management and recycling services to oil and gas producers across major U.S. shale basins. 
Via The Motley Fool
Topics Initial Public Offering
News headline image
Orchestra BioMed Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Ligand (LGND) Q1 2026 Earnings Call Transcript ↗
Ligand (LGND) Q1 2026 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Ligand Pharmaceuticals Q1 Earnings Call Highlights ↗
Ligand Pharmaceuticals (NASDAQ:LGND) reported first-quarter 2026 results that management said reflect the operating leverage of its royalty aggregation strategy, highlighted by growing royalties from... 
Via MarketBeat
Topics Earnings
News headline image
Orchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced Strategic Financing Agreement
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: XOMA Royalty Corporation (Nasdaq – XOMA), Organon & Co. (NYSE – OGN), RE/MAX Holdings, Inc. (NYSE – RMAX), Soleno Therapeutics, Inc. (Nasdaq – SLNO)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Villere St Denis Liquidates $18 Million Euronet Worldwide Stake, According to Recent SEC Filing ↗
Euronet Worldwide encompasses ATM and electronic funds transfer (EFT) services, prepaid distribution, and money transfer, resulting in a more complex structure than that of a typical payments network.... 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Villere St Denis Dumps 134,000 Tidewater (TDW) Shares Worth $9.3 Million ↗
Specializing in offshore marine support, Tidewater serves global energy clients across oil, gas, and windfarm projects. 
Via The Motley Fool
Topics Energy Regulatory Compliance
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: XOMA Royalty Corporation (Nasdaq – XOMA), Organon & Co. (NYSE – OGN), RE/MAX Holdings, Inc. (NYSE – RMAX), Soleno Therapeutics, Inc. (Nasdaq – SLNO)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator
From XOMA Royalty Corporation
Via GlobeNewswire
News headline image
CLO Sells LGND 5,000 Shares for $1.0 Million ↗
Ligand Pharmaceuticals, a leader in drug licensing and royalties, reported a notable insider sale amid strong recent share performance. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Ligand Pharma CFO Sells $688K in Stock as Shares Surge 80% This Past Year. Here's What to Know ↗
This royalty-focused biotech with a broad drug portfolio reported a notable insider sale amid strong stock performance. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Rice Hall James Buys QuidelOrtho Stock ↗
QuidelOrtho develops diagnostic technologies for healthcare providers worldwide, spanning labs, clinics, and retail settings. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Rice Hall James Buys Stride Stock ↗
Stride delivers online and blended education solutions for K-12, career, and adult learners through proprietary technology platforms. 
Via The Motley Fool
News headline image
Ligand Pharma (LGND) Earnings Call Transcript ↗
Ligand Pharma (LGND) Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
The Great Rotation: Small-Caps Break the Mega-Cap Monopoly in Early 2026
The financial landscape of 2026 has opened with a dramatic shift in market leadership, as small-cap stocks stage a historic rally that has left large-cap tech giants in the rearview mirror. After years... 
Via MarketMinute
Topics Artificial Intelligence Earnings Economy
News headline image
This $38.8 Million Vicor Bet Is Getting Bigger Amid a 200% Stock Surge ↗
Vicor Corporation designs advanced power conversion solutions for sectors like aerospace, defense, and industrial automation. 
Via The Motley Fool
News headline image
Sportradar Stock Down 26%, but One Fund Just Disclosed a New $12.6 Million Stake ↗
Specializing in sports data and analytics, Sportradar serves betting operators, leagues, and media with real-time technology solutions. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
What Investors Should Know as One Fund Sells $11 Million of Cavco Industries Stock ↗
This Arizona-based firm provides factory-built homes and modular units to residential and commercial clients across North America. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Fund Sells $23 Million in Globalstar as Stock Surges 170% in One Year ↗
Globalstar delivers satellite communications and IoT connectivity to enterprise and government clients across critical industries worldwide. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Chime Is Down 27% From Its IPO Price, Yet Posting 29% Revenue Growth: Why This New $15 Million Bet Stands Out ↗
This digital banking platform targets U.S. mass market consumers with mobile-first, fee-free services and strategic bank partnerships. 
Via The Motley Fool
Topics Initial Public Offering Regulatory Compliance
News headline image
Solaris Stock Is Up 100% This Past Year, and One Fund Is Betting $29 Million on More Growth ↗
Solaris Energy Infrastructure delivers automation and logistics solutions to U.S. oil and gas operators using proprietary technologies. 
Via The Motley Fool
Topics Energy
News headline image
Stock Up 40% in a Year, $706 Million in Quarterly Sales: Why Boot Barn’s Trimmed Stake Deserves a Look ↗
Boot Barn Holdings operates over 500 stores nationwide, supplying western and workwear apparel to a diverse U.S. customer base. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why Ligand Pharma, A Hidden Name Behind Two Big Drugs, Is Up 88% This Year ↗
Shares of Ligand Pharmaceuticals are absolutely flying as investors line up behind the company's unique royalty-based model. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.